02581nas a2200205   4500008004100000020001400041024001700055245015500072210006900227260029900296300001400595490000700609520160800616100002102224700002402245700001902269700002102288700002102309856004502330       2015                        eng d  a0041-1132  awdn, 041736000aLow-risk transfusion-related acute lung injury donor strategies and the impact on the onset of transfusion-related acute lung injury: a meta-analysis.0 aLowrisk transfusionrelated acute lung injury donor strategies an  a(C) 2015 John Wiley & Sons, Ltdb(1) Department of Intensive Care Medicine, Academic Medical Center, Amsterdam, The Netherlands(2) Laboratory of Experimental Intensive Care and Anesthesiology (LEICA), Academic Medical Center, Amsterdam, The Netherlands(3) Department of Internal Medicine,c2015  a164 - 1750 v553 aBACKGROUND: Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion-related mortality. In the past decade blood banks have implemented low-risk TRALI donor strategies, including a male-only donor policy for plasma-containing blood products to prevent onset of TRALI. We performed a meta-analysis to determine whether use of low-risk TRALI donor strategies for plasma indeed reduces onset of TRALI., STUDY DESIGN AND METHODS: We searched MEDLINE and Cochrane Central Register of Controlled Trials from January 1995 up to January 2013. Two reviewers independently extracted data on study characteristics, methods, and outcomes. Primary endpoint was onset of TRALI. Subgroup analyses were performed for patient populations prone to develop TRALI and general patient populations., RESULTS: Ten articles were included. Meta-analysis using a random-effects model taking into account all transfused products showed a significant reduction for the risk of TRALI after implementation of low-risk TRALI donor strategies (odds ratio [OR], 0.61; 95% confidence interval [CI], 0.42-0.88). Data from patient populations prone to develop TRALI showed a significant reduction of TRALI risk (OR, 0.51; 95% CI, 0.29-0.90), while data from general patient populations showed a similar nonsignificant trend (OR, 0.66; 95% CI, 0.40-1.09). Results were similar when taking only plasma products into account (OR, 0.62; 95% CI, 0.42-0.92)., CONCLUSION: The introduction of low-risk TRALI donor strategies for plasma-containing products results in a reduction of TRALI., (C) 2015 John Wiley & Sons, Ltd1 aMuller, Marcella1 avan Stein, Danielle1 aBinnekade, Jan1 avan Rhenen, Dick1 aVlaar, Alexander  uhttps://notifylibrary.org/reference/4340